ANALYSIS OF GLENMARK SHARE FROM INVESTORS POINT OF VIEW

ANALYSIS OF GLENMARK SHARE FROM INVESTORS POINT OF VIEW

ABOUT GLENMARK

Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Their branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Their API business sells products in over 65 countries including the US, various countries in the EU, South America and India. With 15 manufacturing facilities and 3 R&D centers dedicated to the goal of enriching lives across the globe we believe that the real force behind our continued successes are dedicated employees from across 60 nationalities, committed to creating 'A new way for a new world'.

VALUATION OF GLENMARK SHARE (considering only important values)

Current Price : 410.40 (19.06.2020)

Intrinsic Value:  763.25

Book Value:  208.95

Stock P/E: 16.12

Earnings yield: 9.75 %

Sales Growth (3Yrs): 9.27 %

Sales growth 5Years: 10.44 %

Promoter holding: 46.62 %

Pros:

Company has reduced debt.

Cons:

The company has delivered a poor growth of 10.44% over past five years.

EXPERT VIEWS

This is a very old and strong pharma company. It's current share value is far down from intrinsic value but PE is more. Last ten year it generated only profit. Earning yield looks satisfactory. 

This share looks increase at least Rs. 50 from current level. 

for more opinion about share market whatsapp in 9924764558